Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

American Journal of Hematology - United States
doi 10.1002/ajh.25387
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies

Blood Cancer Journal
OncologyHematology
2018English

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy